Drugs / Bifeprunox
Bifeprunox
also known as
Befeprunox · Bifeprunox mesilate · BIFEPRUNOX MESYLATE · Bifeprunox methanesulfonate · DU-127090
Small molecule targets DRD2, HTR1A via activation
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00581451 | Oct 2007 → Dec 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00139919 | Jan 2006 → Oct 2007 | bipolar disorder, schizoaffective disorder, schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00139906 | Aug 2005 → Oct 2006 | schizoaffective disorder, schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00141479 | May 2005 → Nov 2006 | schizoaffective disorder, schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00141505 | Feb 2005 → Dec 2006 | bipolar I disorder | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT00704509 | Jun 2008 → Aug 2009 | schizophrenia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00658645 | Mar 2008 → Aug 2009 | schizophrenia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00396214 | Apr 2007 → Jan 2008 | schizophrenia | Solvay Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00366327 | Jan 2007 → Mar 2008 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00366171 | Nov 2006 → Oct 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00366704 | Nov 2006 → Mar 2008 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00380224 | Jul 2006 → Sep 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00861497 | Jan 2006 → Jan 2008 | schizophrenia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00160147 | Dec 2005 → Jan 2008 | psychotic disorder | Solvay Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00193687 | Sep 2005 → Jan 2008 | schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00245973 | Jun 2005 → Oct 2007 | bipolar depression | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00134459 | Jun 2005 → May 2006 | bipolar disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00193713 | May 2005 → Nov 2006 | schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00230828 | May 2005 → Jan 2006 | schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifeprunox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00139919 ↗ |
| Known as | Befeprunox | “A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Befeprunox Versus Olanzapine in the Treatment of Outpatients With Schizophrenia.” NCT00380224 ↗ |
| Known as | Bifeprunox mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL218166 ↗ |
| Known as | BIFEPRUNOX MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL218166 ↗ |
| Known as | Bifeprunox methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL218166 ↗ |
| Known as | DU-127090 | ChEMBL registry synonym — accepted as the source's own label CHEMBL218166 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor partial agonist” CHEMBL218166 ↗1“Dopamine D2 receptor partial agonist” CHEMBL218166 ↗ |
| Modality | Small molecule | — CHEMBL218166 ↗ |
| Route | Oral | “52 weeks of fixed oral doses of bifeprunox at 30 mg/day” NCT00396214 ↗ |
| Target | DRD2 | “Dopamine D2 receptor partial agonist” CHEMBL218166 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor partial agonist” CHEMBL218166 ↗ |